Gastrointestinal Cancer

1:30
Selecting the right combination therapy in HCC: challenges
Jean Frédéric Blanc
3:10
Overview of the Spanish GETNE-TRASGU study
Rocio Garcia-Carbonero
1:17
Hitting back at HCC: future landscape of treatment
Jean Frédéric Blanc
1:20
A promising future for drug development in gastrointestinal cancer
Hani Babiker
2:43
Current trials in colorectal cancer investigating panitumumab
Hani Babiker
1:43
Cemiplimab prospects: CRC, CSCC & HNSCC
Hani Babiker
3:40
The gut microbiome: role in causing and detecting colorectal cancer
Paul O'Toole
2:40
Key outcomes of the Phase 1b of atezolizumab and bevacizumab for advanced HCC
Michael Pishvaian
1:48
Upcoming IO combinations for advanced HCC
Michael Pishvaian
2:25
Current therapies for advanced HCC and their limitations
Michael Pishvaian
2:31
Treatment landscape for HCC
Arndt Vogel
2:04
Synergy of anti-androgenic agents and immune checkpoint inhibitors in HCC
Michel Ducreux
3:40
Moving beyond monotherapy in HCC
Arndt Vogel
1:23
Future therapeutic strategies for HCC
Arndt Vogel
1:54
PD-L1 and other biomarkers for renal cell carcinoma
Hans Hammers
1:45
Immuno-oncology in renal cell carcinoma: new combinations are coming
Hans Hammers
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals